Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

162 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Relevance of biopsy-derived pancreatic organoids in the development of efficient transcriptomic signatures to predict adjuvant chemosensitivity in pancreatic cancer.
Nicolle R, Gayet O, Bigonnet M, Roques J, Chanez B, Puleo F, Augustin J, Emile JF, Svrcek M, Arsenijevic T, Hammel P, Rebours V, Giovannini M, Grandval P, Dahan L, Moutardier V, Mitry E, Van Laethem JL, Bachet JB, Cros J, Iovanna J, Dusetti NJ. Nicolle R, et al. Among authors: dahan l. Transl Oncol. 2022 Feb;16:101315. doi: 10.1016/j.tranon.2021.101315. Epub 2021 Dec 11. Transl Oncol. 2022. PMID: 34906890 Free PMC article.
A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma.
Nicolle R, Gayet O, Duconseil P, Vanbrugghe C, Roques J, Bigonnet M, Blum Y, Elarouci N, Armenoult L, Ayadi M, de Reyniès A, Puleo F, Augustin J, Emile JF, Svrcek M, Arsenijevic T, Hammel P, Giovannini M, Grandval P, Dahan L, Moutardier V, Gilabert M, Van Laethem JL, Bachet JB, Cros J, Iovanna J, Dusetti NJ. Nicolle R, et al. Among authors: dahan l. Ann Oncol. 2021 Feb;32(2):250-260. doi: 10.1016/j.annonc.2020.10.601. Epub 2020 Nov 12. Ann Oncol. 2021. PMID: 33188873 Free article.
BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer.
Gonçalves A, Gilabert M, François E, Dahan L, Perrier H, Lamy R, Re D, Largillier R, Gasmi M, Tchiknavorian X, Esterni B, Genre D, Moureau-Zabotto L, Giovannini M, Seitz JF, Delpero JR, Turrini O, Viens P, Raoul JL. Gonçalves A, et al. Among authors: dahan l. Ann Oncol. 2012 Nov;23(11):2799-2805. doi: 10.1093/annonc/mds135. Epub 2012 Jul 5. Ann Oncol. 2012. PMID: 22771827 Free article. Clinical Trial.
Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event End-points in CANcer trials).
Bonnetain F, Bonsing B, Conroy T, Dousseau A, Glimelius B, Haustermans K, Lacaine F, Van Laethem JL, Aparicio T, Aust D, Bassi C, Berger V, Chamorey E, Chibaudel B, Dahan L, De Gramont A, Delpero JR, Dervenis C, Ducreux M, Gal J, Gerber E, Ghaneh P, Hammel P, Hendlisz A, Jooste V, Labianca R, Latouche A, Lutz M, Macarulla T, Malka D, Mauer M, Mitry E, Neoptolemos J, Pessaux P, Sauvanet A, Tabernero J, Taieb J, van Tienhoven G, Gourgou-Bourgade S, Bellera C, Mathoulin-Pélissier S, Collette L. Bonnetain F, et al. Among authors: dahan l. Eur J Cancer. 2014 Nov;50(17):2983-93. doi: 10.1016/j.ejca.2014.07.011. Epub 2014 Sep 22. Eur J Cancer. 2014. PMID: 25256896 Review.
Risk factors of exocrine and endocrine pancreatic insufficiency after pancreatic resection: A multi-center prospective study.
Maignan A, Ouaïssi M, Turrini O, Regenet N, Loundou A, Louis G, Moutardier V, Dahan L, Pirrò N, Sastre B, Delpero JR, Sielezneff I. Maignan A, et al. Among authors: dahan l. J Visc Surg. 2018 Jun;155(3):173-181. doi: 10.1016/j.jviscsurg.2017.10.007. Epub 2018 Feb 1. J Visc Surg. 2018. PMID: 29396112 Free article. Clinical Trial.
Prognostic factors in patients treated with second-line chemotherapy for advanced gastric cancer: results from the randomized prospective phase III FFCD-0307 trial.
Touchefeu Y, Guimbaud R, Louvet C, Dahan L, Samalin E, Barbier E, Le Malicot K, Cohen R, Gornet JM, Aparicio T, Nguyen S, Azzedine A, Etienne PL, Phelip JM, Hammel P, Chapelle N, Sefrioui D, Mineur L, Lepage C, Bouche O. Touchefeu Y, et al. Among authors: dahan l. Gastric Cancer. 2019 May;22(3):577-586. doi: 10.1007/s10120-018-0885-z. Epub 2018 Oct 11. Gastric Cancer. 2019. PMID: 30311042 Clinical Trial.
Induction cisplatin-irinotecan followed by concurrent cisplatin-irinotecan and radiotherapy without surgery in oesophageal cancer: multicenter phase II FFCD trial.
Michel P, Adenis A, Di Fiore F, Boucher E, Galais MP, Dahan L, Mirabel X, Hamidou H, Raoul JL, Jacob JH, Hellot MF, Prod'homme S, Paillot B. Michel P, et al. Among authors: dahan l. Br J Cancer. 2006 Sep 18;95(6):705-9. doi: 10.1038/sj.bjc.6603328. Br J Cancer. 2006. PMID: 16967056 Free PMC article. Clinical Trial.
162 results